February 14, 2023

Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 14, 2023 Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

RADNOR, Pa., Feb. 14, 2023 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven …

Continue reading “Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares”

February 9, 2023 Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering

RADNOR, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven …

Continue reading “Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering”

January 24, 2023 Aculys Pharma Initiates a Phase 3 Trial of pitolisant Treating Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Syndrome

Minato-ku, Tokyo, Japan, January 24 2023 — Aculys Pharma, Inc. (“Aculys”), a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, announced …

Continue reading “Aculys Pharma Initiates a Phase 3 Trial of pitolisant Treating Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Syndrome”

January 18, 2023 Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies

Abingworth, a leading transatlantic life sciences investment firm and part of global investment firm Carlyle (NASDAQ: CG), led financings and was joined by Carlyle, OrbiMed, …

Continue reading “Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Studies”

January 8, 2023 Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as …

Continue reading “Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)”

November 10, 2022 Aculys Pharma initiates a phase 3 clinical study of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures

Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Minato-ku, Tokyo; Representative Director and CEO: Kazunari Tsunaba), a company focused on the development and commercialization of new innovative …

Continue reading “Aculys Pharma initiates a phase 3 clinical study of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures”

November 8, 2022 Aculys Pharma initiates a phase 3 clinical study of the histamine H3 receptor antagonist/inverse agonist pitolisant in patients with narcolepsy in Japan

Continue reading “Aculys Pharma initiates a phase 3 clinical study of the histamine H3 receptor antagonist/inverse agonist pitolisant in patients with narcolepsy in Japan”

May 3, 2022 Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

VOQUEZNA TRIPLE and DUAL PAKs each contain vonoprazan, a novel, first-in-class potassium-competitive acid blocker (PCAB), and have demonstrated superior eradication rates vs. lansoprazole-based triple therapy …

Continue reading “Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults”

May 3, 2022 HilleVax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the …

Continue reading “HilleVax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares”

May 2, 2022 HilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants

BOSTON, May 02, 2022 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, reported …

Continue reading “HilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants”

March 30, 2022 Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis

FLORHAM PARK, N.J., March 14, 2022 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel …

Continue reading “Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis”

March 28, 2022 Aculys Pharma Closes US$24 Million Series B Financing

Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representative Director and CEO: Kazunari Tsunaba), a new biopharmaceutical company focused on the development and …

Continue reading “Aculys Pharma Closes US$24 Million Series B Financing”

March 23, 2022 Catalys Pacific Launches Kirilys Therapeutics as a Multi-asset Precision Oncology Company

SAN FRANCISCO–(BUSINESS WIRE)–Kirilys Therapeutics, Inc., a private, preclinical-stage biopharmaceutical company founded by investment firm Catalys Pacific, announced today that the Company completed a seed financing …

Continue reading “Catalys Pacific Launches Kirilys Therapeutics as a Multi-asset Precision Oncology Company”

March 10, 2022 Catalys Pacific Calls for Economical Disengagement from Russian Industry

Catalys Pacific would like to inform that we have signed onto an open letter to call for the global business community to economically disengage from …

Continue reading “Catalys Pacific Calls for Economical Disengagement from Russian Industry”

March 2, 2022 Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease

– Company Acquires License to EA Pharma’s Upacicalcet Worldwide Outside of Japan and Asia – Industry Veteran Neal Fowler Named Chief Executive Officer of New …

Continue reading “Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease”

February 4, 2022 Aculys Pharma Initiated a Phase 1 Clinical Trial of pitolisant, a histamine H3 receptor antagonist / inverse agonist, in Japan

Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representative Director and CEO: Kazunari Tsunaba), a biopharmaceutical company focused on the development and commercialization …

Continue reading “Aculys Pharma Initiated a Phase 1 Clinical Trial of pitolisant, a histamine H3 receptor antagonist / inverse agonist, in Japan”

January 26, 2022 Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO®

Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO® (diazepam nasal spray), a nasal spray approved by …

Continue reading “Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO®”

October 29, 2021 Aculys Pharma Closes US$60 Million Series A Financing Led by SoftBank Vision Fund 2

Aculys Pharma, Inc. (“Aculys Pharma”), a new biopharmaceutical company focused on the development and commercialization of new innovative drugs in the fields of neurology and …

Continue reading “Aculys Pharma Closes US$60 Million Series A Financing Led by SoftBank Vision Fund 2”

October 18, 2021 Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial

Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phases Vonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 …

Continue reading “Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial”

September 8, 2021 Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection

FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel …

Continue reading “Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection”

September 8, 2021 HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

Financing led by Frazier Healthcare Partners with strong life science investor syndicate Julie Gerberding, MD, MPH, Jeri Hilleman, Jaime Sepulveda, MD, DSc, MPH, Susan Silbermann, …

Continue reading “HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate”

April 29, 2021 Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints

• Both vonoprazan-based treatment regimens demonstrated superior eradication rates vs. a standard of care proton pump inhibitor (PPI)-based triple therapy • New Drug Application (NDA) …

Continue reading “Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints”

April 6, 2021 Mineralys Therapeutics Closes $40 Million Series A Funding

PHILADELPHIA, PA, April 6, 2021 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific, announced today that the Company completed a …

Continue reading “Mineralys Therapeutics Closes $40 Million Series A Funding”

January 19, 2021 Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial

FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel …

Continue reading “Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial”

November 30, 2020 Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial

Topline results expected in second half of 2021 FLORHAM PARK, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage …

Continue reading “Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial”

July 16, 2020 Domain Associates and Catalys Pacific Launch Exalys Therapeutics to Develop Portfolio of Next-Generation EP4 Antagonists

San Francisco, Calif., July 16, 2020 Company Focused on Developing New Medicines for Postoperative Delirium and Other Inflammatory Disorders Domain Associates and Catalys Pacific today …

Continue reading “Domain Associates and Catalys Pacific Launch Exalys Therapeutics to Develop Portfolio of Next-Generation EP4 Antagonists”

October 24th, 2019 Phathom Pharmaceuticals Announces Pricing of Initial Public Offering and Begin trading on the Nasdaq

BUFFALO GROVE, Ill.–(BUSINESS WIRE)–Oct. 24, 2019– Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal …

Continue reading “Phathom Pharmaceuticals Announces Pricing of Initial Public Offering and Begin trading on the Nasdaq”

July 23, 2019 Japanese Foreign Minister’s Commendations for FY 2019 to Dr. Slingsby, Founder & Managing Partner of Catalys Pacific

Catalys Pacific is delighted to announce that, on July 16th, 2019, Founder & Managing Partner of Catalys Pacific, Dr. BT Slingsby, received the Japanese Foreign …

Continue reading “Japanese Foreign Minister’s Commendations for FY 2019 to Dr. Slingsby, Founder & Managing Partner of Catalys Pacific”

June 17, 2019 Catalys Pacific Launches in Japan to Advance Early-Stage Life Sciences Innovation by Creating and Investing in Global Companies

Tokyo, Japan – 17 June 2019 Catalys Pacific, a new venture capital firm in Japan built by a global team seasoned in life sciences investing, …

Continue reading “Catalys Pacific Launches in Japan to Advance Early-Stage Life Sciences Innovation by Creating and Investing in Global Companies”

Featured New Currents Explore new currents from our firm